Biolegend, 312604, FITC anti-human CD158b/j (KIR2DL2/L3/S2) Antibody, 100tests

CD158b is expressed on natural killer cells and a subset of T cells. It is a member of the immunoglobulin superfamily containing two immunoglobulin C2-type domains. Both variants and alternative isoforms of CD158b have been reported. The interaction of CD158b with specific HLA-C antigens on a target cell (HLA-Cw1, HLA-Cw3, HLA-Cw7 alleles, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK cell and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.
100tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)
Application Notes: The DX27 monoclonal antibody reacts with a common epitope of KIR2DL2 (CD158b1, p58.2), KIR2DL3 (CD158b2, p58.3), and KIR2DS2 (CD158j, p50.2). Additional reported applications (for the relevant formats) include: restoring the NK cell cytotoxicity1,5.This clone has been tested in-house and determined to not be suitable for applications in immunohistochemistry of paraffin-embedded tissue sections (IHC-P).
Application References(PubMed link indicates BioLegend citation): Bakker ABH, et al. 1998. J. Immunol. 160:5239. Lucas M, et al. 2003. J. Virol. 77:2251. Goodier M, et al. 2000. J. Immunol. 165:139. Yawata M, et al. 2002. Immunogenetics 54:543. Valiante NM, et al. 1997. Immunity 7:739.
Product Citations: Busch A, et al. 2008. J Immunol. 181:3965. PubMed Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed Crellin N, et al. 2010. J Exp Med. 207:281. PubMed Gruber CN, et al. 2020. Immunity. 53(3):672-684. PubMed Reches A, et al. 2016. J Immunol. 196: 4967 - 4976. PubMed Goodridge J, et al. 2013. J Immunol. 191:3553. PubMed Kwant-Mitchell A, et al. 2009. PLoS One. 4:e8379. PubMed Harris LD, et al. 2020. Front Cell Infect Microbiol. 10:120. PubMed Bennstein SB, et al. 2020. eLife. 9:e55232.. PubMed
RRID: AB_314934 (BioLegend Cat. No. 312603) AB_2296486 (BioLegend Cat. No. 312604)
Structure: Immunoglobulin superfamily member, contains two immunoglobulin C2-type domains, type I membrane protein
Distribution: NK cells and a subset of T cells
Function: Inhibits cytotoxic function of NK and T cells upon interacting with specific HLA-C antigens on target cell
Ligand/Receptor: HLA-C antigens such as HLA-Cw1, HLA-Cw3, HLA-Cw7
Cell Type: NK cells, T cells
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: 1. Colonna M, et al. 1995. Science 268:405. 2. Uhrburg M, et al. 1997. Immunity 7:753. 3. Wagtmann N, et al. 1995. Immunity 3:801. 4. Dohring C, et al. 1996. Immunogenetics 44:227. 5. Maenaka K, et al. 1999. Structure 7:391.
Gene ID: 3803
UniProt: View information about CD158b/j on UniProt.org
Clone: DX27
Regulatory Status: RUO
Other Names: CD158b1 (KIR2DL2, p58.2), CD158b2 (KIR2DL3, p58.3), CD158j (KIR2DS2, p50.2), KIR-NKAT2, CD158b/CD158j
Isotype: Mouse IgG2a, κ